These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 16844285)

  • 1. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
    Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
    Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
    Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
    Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma.
    Feldman AL; Alexander HR; Yang JC; Linehan WM; Eyler RA; Miller MS; Steinberg SM; Libutti SK
    Cancer; 2002 Oct; 95(8):1637-43. PubMed ID: 12365010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma.
    Jacobsen J; Rasmuson T; Grankvist K; Ljungberg B
    J Urol; 2000 Jan; 163(1):343-7. PubMed ID: 10604387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
    Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of serum levels of endostatin in patients with clear cell renal cell carcinoma].
    Guan KP; Xiao ZD; Wang D; Shi HZ; Guan YY; Lu L; Han SJ; Li CL
    Zhonghua Wai Ke Za Zhi; 2009 May; 47(10):737-9. PubMed ID: 19615205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.
    Poon RT; Ho JW; Tong CS; Lau C; Ng IO; Fan ST
    Br J Surg; 2004 Oct; 91(10):1354-60. PubMed ID: 15376182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P; Teerenhovi L; Joensuu H
    Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
    Seko Y; Fukuda S; Nagai R
    Clin Sci (Lond); 2004 May; 106(5):439-42. PubMed ID: 14965340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
    Uematsu S; Higashi T; Nouso K; Kariyama K; Nakamura S; Suzuki M; Nakatsukasa H; Kobayashi Y; Hanafusa T; Tsuji T; Shiratori Y
    J Gastroenterol Hepatol; 2005 Apr; 20(4):583-8. PubMed ID: 15836707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
    Edgren M; Lennernäs B; Larsson A; Kälkner KM
    Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.
    De Vita F; Orditura M; Lieto E; Infusino S; Morgillo F; Martinelli E; Castellano P; Romano C; Ciardiello F; Catalano G; Pignatelli C; Galizia G
    Cancer; 2004 Jan; 100(2):270-8. PubMed ID: 14716760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of angiogenic factor levels in tumor drainage and peripheral venous blood from colorectal cancer patients.
    Tien YW; Chang KJ; Chiu YF; Huang KW; Lee PH
    Ann Surg Oncol; 2006 Nov; 13(11):1357-63. PubMed ID: 17001510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
    Urbańska-Ryś H; Robak T
    Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.
    Dhar DK; Ono T; Yamanoi A; Soda Y; Yamaguchi E; Rahman MA; Kohno H; Nagasue N
    Cancer; 2002 Nov; 95(10):2188-95. PubMed ID: 12412173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
    Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
    J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.